In reply: Is diabetes still a compelling indication for renin-angiotensin-aldosterone system inhibitors?

We would like to thank Dr. Fakheri and colleagues for their extremely helpful comments on our recent review of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs).[1][1] We agree entirely with their suggestion on the lack of current data on any superiority of